Latest research on Methylphenidate

A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine. [PubChem]

Latest findings

The main treatment of ADHD is the use of stimulant drugs such as Methylphenidate. [source, 2016]
For all children in each three groups, the main treatment of the disease (Methylphenidate, Ritalin®; Produced by Novartis Pharmaceutical Company in Switzerland) was prescribed based on child's weight (10 mg daily for children under 20 kg; 10 mg, twice a day for children over 20 kg). [source, 2016]
ADHD patients in an omega-3 group beside the main drug (Methylphenidate) have not significant difference compared to C group in Conners’ scales mean in all periods during 8 weeks after treatment. [source, 2016]
Regarding our results as well as due to lack of different micronutrients such as zinc in Iran, use of zinc supplement in addition to main medications (Methylphenidate) in children with ADHD has been recommended. [source, 2016]
Specifically, Adderall XR® (Amphetamine mixed salts [MAS-XR]; Shire Canada Inc.), Concerta® (Methylphenidate HCl extended release [OROS-MPH]; Janssen Inc., Toronto, ON, Canada) and generic, Biphentin® (Methylphenidate HCl controlled release [MPH-CR]; Purdue Pharma, Pickering, ON, Canada) and Vyvanse® (Lisdexamfetamine dimesylate [LDX]; Shire Canada Inc.) are available in Canada for the treatment of ADHD [18, 19]. [source, 2016]
All patients were treated with Methylphenidate (MPH) and followed for at least 2 months with moderate doses (eight patients tried MPH immediate release in daily doses between 20 and 35 mg, two patients MPH long acting agents 60–80 mg, and one patient tried osmotic-release oral system MPH 72–108 mg). [source, 2016]
Such pharmacological cognitive enhancement (PCE) may be achieved through the use of psychostimulants like Methylphenidate (e.g., Ritalin®) and wakefulness-promoting drugs like Modafinil (e.g., Provigil®). [source, 2016]
After 1 year, 85% of patients were on Methylphenidate (mean: 25.5±8.7 mg/day; 0.87±0.34 mg/kg/day) and 15% on dexamphetamine (mean: 10.4±4.8 mg/day; 0.30±0.15 mg/kg/day), with 31% taking the same dose every day and 58% taking medication on school days but less often or not at all on nonschool days. [source, 2016]
After 3 years, 93% were on Methylphenidate (mean: 35.2±16.3 mg/day; 1.00±0.45 mg/kg/day) and 7% on dexamphetamine (mean: 10.0±2.5 mg/day; 0.34±0.08 mg/kg/day); 42% took the same dose every day and 51% took medication on school days but less often or not at all on nonschool days. [source, 2016]
The main reason for changing from dexamphetamine to Methylphenidate was the availability of subsidized sustained release formulations for Methylphenidate, which were taken by 34% at 1 year and by 72% at 3 years. [source, 2016]